«What we've discovered will help clinicians to better
treat women with ovarian cancer,» says Dr. Ben Tsang, senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa.
Not exact matches
The drug is meant for
women with advanced
ovarian cancer who have already been
treated with two or more chemotherapies.
By the time of diagnosis the majority of
women with ovarian cancer already have extensive spread of the disease which makes it difficult to
treat by surgery or chemotherapy.
«For decades,
women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Insti
women have been
treated with a combination of treatment options, resulting in poor prognosis for most
women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Insti
women with advanced - stage
ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at
Women's College Research Insti
Women's College Research Institute.
More than 80 percent of
women with advanced stage high - grade serous
ovarian cancer experience relapses even after repeated surgeries and multiple rounds of chemotherapy, and this effective new approach to
treat the disease could be a major step forward in preventing
cancer from returning.
In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in
women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory
cancer by injecting tumor tissues obtained from gynecological
cancer patients treated at the Cancer Institute into laboratory
cancer patients
treated at the
Cancer Institute into laboratory
Cancer Institute into laboratory mice.
Treating women with olaparib, a new type of experimental drug called a PARP inhibitor, after their initial
cancer treatment, may help prevent their
ovarian cancer from coming back, according to a phase - II clinical trial led by UK scientists.